Ascendis Pharma (ASND): Patent Peace Takes 18% to 20% of Covered YUVIWEL Sales

Patent Peace Comes With a Revenue Toll

On August 31, 2026, Ascendis Pharma entered a binding term sheet with BioMarin Pharmaceutical to settle global patent disputes regarding YUVIWEL (navepegritide), its once-weekly therapy for achondroplasia. The agreement terminates active litigation, including an investigation before the U.S. International Trade Commission, granting Ascendis a non-exclusive worldwide license. In exchange, Ascendis agreed to pay BioMarin a 20% royalty on covered U.S. net sales, retroactive to the first commercial sale, and an 18% royalty on net sales across the European Union, Brazil, and South Korea through May 2030.

That royalty structure claims roughly one-fifth of top-line product realization before Ascendis absorbs the commercial infrastructure and marketing costs needed to scale the drug globally. YUVIWEL generated €8 million in product revenue during Q2 2026 following its initial launch, registering more than 220 unique U.S. commercial enrollments through July 31, 2026, with reimbursement approval exceeding 65% across those reported cases. At the same time, company-wide selling, general, and administrative expenses reached €173 million in Q2 2026, up from €145 million in the prior quarter, underscoring the heavy ongoing capital commitments of simultaneous commercial rollouts.

StockLens's model rated Ascendis Solid with a Composite score of 75 as of September 1, 2026, summarizing an underlying tension between accelerating commercial revenue and financial quality. That reading reflects fundamental data recorded before the August 31 agreement and does not incorporate the specific financial obligations established under the BioMarin settlement.

Fast Growth Still Has to Turn Into Durable Cash

The patent settlement intersects an existing divergence within Ascendis's fundamental metrics. In the healthcare sector, the company records a Growth score of 88, driven by total Q2 2026 product revenue of €315 million, a 105% increase year over year led by €252 million from YORVIPATH and €55 million from SKYTROFA. In contrast, Ascendis posts an Efficiency score of 25, reflecting that reported accrual earnings continue to outpace cash collection.

This operational dynamic creates a clear cross-current between accounting coverage and underlying liquidity. Operating earnings based on EBIT do not fully cover interest obligations, yet cash generation and positive operational liquidity mitigate near-term debt-service strain. Ascendis closed Q2 2026 with €812.3 million in cash and equivalents after generating €274 million in operating cash flow during the first half of the year, while management reiterated its expectation for full-year 2026 cash flow from operating activities to exceed €500 million. Separately, external estimates for the Forward EPS Growth factor project a 47.5% decline, distinct from reported Q2 2026 non-IFRS diluted earnings of €0.90 per share.